Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic
effect on remote and non-irradiated tumor deposits, which is called abscopal effect. The view …

Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a
central focus for engaging the immune system in the fight against cancer. Basic science …

T cells and natural killer (NK) cells have complementary roles in tumor immunity, and dual T
cell and NK cell attack thus offers opportunities to deepen the impact of immunotherapy …